John R. Ingram, Martina Porter, Raj Chovatiya, E. Giamarellos‐Bourboulis, Falk G. Bechara, Hideki Fujita, Wayne Gulliver, Edward Muller, Muhammad Bari, Robert Rolleri, Rob Byerly, Joslyn S Kirby
{"title":"比美单抗在中度至重度化脓性扁桃体炎患者中的应答维持至 48 周：3 期双盲安慰剂对照随机临床试验 BE HEARD I 和 II 的应答者汇总分析","authors":"John R. Ingram, Martina Porter, Raj Chovatiya, E. Giamarellos‐Bourboulis, Falk G. Bechara, Hideki Fujita, Wayne Gulliver, Edward Muller, Muhammad Bari, Robert Rolleri, Rob Byerly, Joslyn S Kirby","doi":"10.25251/skin.8.supp.396","DOIUrl":null,"url":null,"abstract":"<jats:p>N/A</jats:p>","PeriodicalId":22013,"journal":{"name":"SKIN The Journal of Cutaneous Medicine","volume":"41 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II\",\"authors\":\"John R. Ingram, Martina Porter, Raj Chovatiya, E. Giamarellos‐Bourboulis, Falk G. Bechara, Hideki Fujita, Wayne Gulliver, Edward Muller, Muhammad Bari, Robert Rolleri, Rob Byerly, Joslyn S Kirby\",\"doi\":\"10.25251/skin.8.supp.396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<jats:p>N/A</jats:p>\",\"PeriodicalId\":22013,\"journal\":{\"name\":\"SKIN The Journal of Cutaneous Medicine\",\"volume\":\"41 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SKIN The Journal of Cutaneous Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25251/skin.8.supp.396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SKIN The Journal of Cutaneous Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25251/skin.8.supp.396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
